Rivastigmine in Mild Alzheimer's Disease, FMRI Study

• Status: Completed
• Trial end date: 2008-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kuopio University Hospital
• Treatments: Rivastigmine

Criteria

Inclusion Criteria:

• Probable Alzheimer's disease according to the NINCDS-ADRDA criteria

• mild disease, CDR 1

• the clinician is planning to start anticholinesterase treatment

Exclusion Criteria:

• cognitive impairment for other reason than Alzheimer's disease

• severe depression

• other unstable physical disease

• medal in body prevention MRI examination, claustrophobia

• cardiac pacemaker

• other significant neurologic or psychiatric disease

• contraindication for anticholinesterase treatment